A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.
about
Open drug discovery for the Zika virusDiscriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophoresFinding small molecules for the 'next Ebola'Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig modelSmall molecules with antiviral activity against the Ebola virusCharacterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions.Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.Machine learning models identify molecules active against the Ebola virus in vitroThe Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencingFDA approved drugs as potential Ebola treatments.Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40.Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseasesRepurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.The new alchemy: Online networking, data sharing and research activity distribution tools for scientists.Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus
P2860
Q22676298-A9E88FEB-E1F2-4654-B6A3-129206F50153Q27902257-2C988D4D-5003-4760-BD46-86F2293054ACQ28649345-CB676E55-FEE4-4BBD-B8DD-9379A973D425Q33617999-A3E95F38-8090-4165-B906-3FC09A9E066DQ34464403-7E27C195-8A26-4A35-BDC2-BC35AA8F9989Q35086957-CF81DC4F-46CD-41AD-B15F-28A23E3DEFD8Q35605579-6ACED7D7-E268-49C8-91AF-A1A608109B44Q35689217-B73C5D35-A5CA-4689-B93F-09333758172DQ35911643-710CF4B5-047C-4150-8193-5E8CC80CA0E6Q36411422-F8B31AE4-21E9-4846-A007-24759582DF21Q39027505-BD5017BD-7AFA-4725-9246-2CFA5CEE6ECCQ39216411-18889F78-73CC-4F65-BC01-4BC151C62303Q39360987-C88AAEE9-31B3-4BA4-965A-C9EEC8300466Q40045378-73900F30-0EDD-4CA5-9F1F-CC5609A995E7Q41589110-312A6D0E-F494-424A-93CD-97012E38747DQ56535662-7BCA541B-8FC7-4CEB-8394-3C6887FE15A4
P2860
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.
@en
type
label
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.
@en
prefLabel
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.
@en
P2860
P1433
P1476
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
@en
P2093
Joel S Freundlich
Megan Coffee
P2860
P356
10.12688/F1000RESEARCH.5741.2
P50
P577
2014-11-14T00:00:00Z